Notice of Intent -- CELLINK.docx

Hospital and Laboratory Support Division Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM)

Title: Cellink BIO X Advanced Multi-Material 3D Bioprinting System for Cancer Biology and Organoid Research

Presolicitation

SYNOPSIS 75N98026Q01018

SYNOPSIS 75N98026Q01018

General Information

Contracting Office Address

National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817

Description

INTRODUCTION

THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to:

CELLINK LLC

2000 Kraft Dr. Suite 2125 Blacksburg, VA 24060 United States

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

The intended procurement is classified under NAICS code 811210 with a Size Standard $34M.

REGULATORY AUTHORITY

The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-99-1, July 16, 2018. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000).

STATUTORY AUTHORITY

This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

GENERAL INFORMATION

1. Title: Cellink BIO X Advanced Multi-Material 3D Bioprinting System for Cancer Biology and Organoid Research

2. Background Information: The Muthuswamy Laboratory investigates mechanisms of tumor initiation, progression, and therapeutic response using advanced three-dimensional (3D) culture systems, organoid models, and engineered tissue microenvironments. Current research focuses on understanding interactions between tumor cells and their surrounding stromal and extracellular matrix environments that influence cancer development and treatment response.

Existing laboratory methods for generating 3D tissue models rely on manual preparation techniques that introduce variability in construct geometry, cell distribution, and extracellular matrix composition. These limitations reduce experimental reproducibility and restrict the complexity of tissue models that can be generated. To support ongoing NIH-funded research, the Muthuswamy Laboratory requires a high-precision 3D bioprinting platform capable of reproducibly fabricating multicellular tissue constructs using a variety of bioinks and biomaterials. The system must integrate with existing cell culture, microscopy, and downstream molecular analysis workflows while enabling standardized production of physiologically relevant in vitro models.

CLOSING STATEMENT

This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by August 24th 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98026Q01018. Responses may be submitted electronically to Mr. Vishnuvajjala Hanumanth Rao, Lead Purchasing Agent, at vishnuh@mail.nih.gov. Fax responses will not be accepted.

"All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”

image1.png